Christa Flechtenmacher

Christa Flechtenmacher

Auto-generated profile, based on publicly available information

Christa Flechtenmacher

Institute of Pathology, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Gastroenterology
Verified
Journal Article
Open access
TAThomas Albrecht
Thomas Albrecht
ARAnnik Rossberg
Annik Rossberg
JAJana Dorothea Albrecht
Jana Dorothea Albrecht
JNJan Peter Nicolay
Jan Peter Nicolay
BSBeate Straub
Beate Straub
BGBenjamin Goeppert
Benjamin Goeppert
Diagnosis of adenocarcinoma in the liver is a frequent scenario in routine pathology and has a critical impact on clinical decision-making. However, rendering a correct diagnosis can be challenging and often requires the integration of clinical, radiological, and immunohistochemical information. We present a deep learning model (HEPNET) to distinguish intrahepatic cholangiocarcinoma (iCCA) from colorectal liver metastasis (CRM) as the most frequent primary and secondary forms of liver adenocarcinoma with clinical-grade accuracy using hematoxylin and eosin-stained whole-slide images. HEPNET was trained on 714 589 image tiles from 456 patients who were randomly selected in a stratified manner from a pool of 571 patients who underwent surgical resection or biopsy at Heidelberg University Hospital. Model performance was evaluated on a hold-out internal test set comprising 115 patients and externally validated on 159 patients recruited at Mainz University Hospital. On the hold-out internal test set, HEPNET achieved an area under the receiver operating characteristic curve (AUROC) of 0.994 (95% CI 0.989-1.000) and an accuracy of 96.522% (95% CI 94.521-98.694%) at the patient level. Validation on the external test set yielded an AUROC of 0.997 (95% CI 0.995-1.000), corresponding to an accuracy of 98.113% (95% CI 96.907-100.000%). HEPNET surpassed the performance of six pathology experts with different levels of experience in a reader study of 50 patients (P=.0005), boosted the performance of resident pathologists to the level of senior pathologists, and reduced potential downstream analyses. Here, we provide a ready-to-use tool with a clinical-grade performance that may facilitate routine pathology by rendering a definitive diagnosis and guiding ancillary testing. The incorporation of HEPNET into pathology laboratories may optimize the diagnostic workflow, complemented by test-related labor and cost savings.

1 April 2004 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CWChristina Wolf
Christina Wolf
CFChrista Flechtenmacher
Christa Flechtenmacher
ADAndreas Dietz
Andreas Dietz
HWHagen Weidauer
Hagen Weidauer
UAUlrich Abel
Ulrich Abel
FBFranz X. Bosch
Franz X. Bosch

1 May 2002 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
CZChristoph Mike Ziegler
Christoph Mike Ziegler
CFChrista Flechtenmacher
Christa Flechtenmacher
JMJoachim Mühling
Joachim Mühling

1 December 2004 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
GSG. Szabó
G. Szabó
LSL. Seres
L. Seres
PSP. Soós
P. Soós
CFC. Flechtenmacher
C. Flechtenmacher
ZZZsuzsanna Kinga Zsengeller
Zsuzsanna Kinga Zsengeller
SHS. Hagl
S. Hagl
Background: We investigated the effects of PARS inhibition on intestinal injury in a canine model of cardiopulmonary bypass (CPB). Methods: Twelve dogs underwent 90 minutes of hypothermic CPB. 6 dogs received 5 mg/kg PJ34, a selective PARP inhibitor during CPB, 6 vehicle-treated animals served as controls. Mesenteric blood flow (MBF) and mesenteric vascular resistance (MVR) were measured before and 60 minutes after weaning from CPB. Endothelium-dependent vasorelaxation to acetylcholine (ACH) and endothelium-independent vasorelaxation to sodium-nitroprussid (SNP) were expressed as percent change of MVR. In addition, mesenteric creatinkinase (CK) and lactate release were determined. Results: Baseline hemodynamics, MBF, response to ACH (- 41 ± 3 vs. - 55 ± 6 %) and SNP (- 60 ± 2 vs. - 56 ± 4 %) did not differ significantly between the groups. The response to ACH decreased significantly in the control group while it remained unchanged in the PJ34 group (- 29 ± 5 vs. - 46 ± 9 %, p < 0.05). The response to SNP did not change. Mesenteric CK release (325 ± 99 vs. 16 ± 10 U/l, p < 0.05) and lactate production (0.96 ± 0.17 vs. 0.4 ± 0.2 mmol/l, p < 0.05) were significantly lower in the PJ34 group. Conclusion: PARP inhibition prevents CPB-induced mesenteric endothelial dysfunction and tissue damage. 1 This study was presented at the 4th Joint Meeting of the German, Austrian, and Swiss Society for Thoracic and Cardiovascular Surgery, Hamburg, February 15 - 18, 2004

1 January 2025 in Case Reports in Hepatology
Verified
Journal Article
Open access
TRThomas Rösner
Thomas Rösner
JGJulia Grenz
Julia Grenz
MSMarlene Schaumäker
Marlene Schaumäker
SCSven Cuntz
Sven Cuntz
NBNorbert Blank
Norbert Blank
IMIsabelle Mohr
Isabelle Mohr
Herpes simplex virus (HSV) infections are common in the European population, typically presenting with mucocutaneous and anogenital manifestations. However, disseminated infections and organ involvement are rare, usually occurring in immunocompromised individuals, particularly after hematopoietic stem cell or solid organ transplantation. HSV1/2‐induced hepatitis is infrequent but can result in acute liver failure (ALF) and increased mortality. We present a case of fulminant ALF caused by disseminated primary HSV2 infection in a fifty‐year‐old male with rheumatoid arthritis treated with the JAK‐inhibitor upadacitinib for 3 months prior to presentation. Clinical examination revealed severe oropharyngeal mucositis and hepatic encephalopathy. Initial laboratory results showed bicytopenia, significantly elevated transaminases, bilirubin, inflammatory markers, and severe coagulopathy. Empirical treatment with an antimicrobial regimen, intravenous aciclovir, acetylcysteine, and plasmapheresis (PPH) was initiated. The patient was listed for urgent liver transplantation based on King’s College criteria. Further investigations revealed a high viral load of HSV2 DNA in the blood, and transjugular liver biopsy confirmed extensive liver necrosis with positive HSV staining. Despite antiviral therapy, the HSV2 viral load remained high, indicating resistance, and the patient was deemed “nontransplantable” due to clinical deterioration with progressive hepatic coma, hemorrhagic–septic shock, multiorgan failure, and secondary bowel ischemia, ultimately leading to the patient’s death from refractory shock. This is only the second documented case of fulminant ALF due to HSV2 hepatitis in a patient undergoing JAK inhibition, and the first involving upadacitinib. It highlights the importance of considering primary herpesvirus infection as a potential cause of ALF, particularly in immunocompromised patients, and underscores the need for early antiviral intervention to improve outcomes.

1 January 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
FMFlora Magnotti
Flora Magnotti
SVSéverine Valsesia
Séverine Valsesia
PGPurnima Gupta
Purnima Gupta
CFChrista Flechtenmacher
Christa Flechtenmacher
PCPierre Contard
Pierre Contard
THThomas Henry
Thomas Henry